semaglutide oral cardiovascular indication 2025 news ACC 2025: Reduces Events by 14% at 4 Years FDA approves oral semaglutide for

Both drugs contain semaglutide, a synthetic version of a hormone known as GLP-1, which the body releases into the intestine when people eat food, reducing feelings of hunger

Moore A, Bidonde J, Fisher E, Huser W, Bell RF, Perrot S, Makri S, Straube S

For weight management , semaglutide helps support appetite control and is used along with a reduced-calorie eating plan and increased physical activity in eligible patients

With newer GLP-1based therapies now emerging, the field has an opportunity to test whether different drugs in this class have distinct effects on aging biology and to identify which patients may benefit most. Larger clinical trials are needed to confirm the findings, determine how long treatment effects last, and establish optimal dosing and treatment duration for both people with HIV and the broader population